Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC_VEROne
2024-515981-14-00Phase 3Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Nov 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab, cisplatin, doxorubicin, fluorouracil, docetaxel and 2 more in gastric adenocarcinoma (2 arms), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoints: Secondary resectability rate and Progression-free survival at 1 and 3 years. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2024-515981-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515981-14-00.